Literature DB >> 9202780

Morphology and immunohistochemistry of a symptomatic septum pellucidum cavum Vergae cyst in man.

E Ronsin1, D Grosskopf, J Perre.   

Abstract

The cavum septi pellucidi (CSP) and cavum Vergae (CV) are persistent, primitive, or acquired, midline structures of adult human brain. It is customary to distinguish between the non-communicating and the communicating cava, depending on whether the cavum communicates with the cerebral ventricular system or not. Only a few cases of symptomatic non-communicating cava, called septum pellucidum and cavum Vergae cysts, have been described in the literature. In this study, the authors describe the morphological, histological and histo-immunological characteristics of an additional case of septum pellucidum-cavum Vergae cyst in a forty-year-old man who died the day following a ventriculo-peritoneal shunt. We have found a communication between the CSP and the leptomeningeal space of the anterior interhemispheric fissure, in the absence of subarachnoid haemorrhage. The authors discuss the origin of the intracystic fluid and the classification of the CSP.

Entities:  

Mesh:

Year:  1997        PMID: 9202780     DOI: 10.1007/bf01808836

Source DB:  PubMed          Journal:  Acta Neurochir (Wien)        ISSN: 0001-6268            Impact factor:   2.216


  3 in total

1.  Operative indications and neuroendoscopic management of symptomatic cysts of the septum pellucidum.

Authors:  Tamotsu Miki; Jun Wada; Nobuyuki Nakajima; Tadayoshi Inaji; Jiro Akimoto; Jo Haraoka
Journal:  Childs Nerv Syst       Date:  2005-01-15       Impact factor: 1.475

2.  The corpus callosum, the other great forebrain commissures, and the septum pellucidum: anatomy, development, and malformation.

Authors:  Charles Raybaud
Journal:  Neuroradiology       Date:  2010-04-27       Impact factor: 2.804

3.  Expanding Cyst of the Septum Pellucidum - Endoscopic Observations on the Mechanism of Development and Results of Treatment.

Authors:  Leszek Sagan; Bartosz Limanówka; Leszek Herbowski; Wojciech Poncyljusz; Maria Giżewska
Journal:  Neurol Med Chir (Tokyo)       Date:  2020-03-05       Impact factor: 1.742

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.